newsfilter
← Latest News
GlobeNewswire·

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • On October 13, 2025, Tvardi shares fell over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial for TTI-101.
  • The clinical trial aimed to assess safety, pharmacokinetics, & exploratory lung function outcomes in patients with idiopathic pulmonary fibrosis.
  • Tvardi concluded the study did not meet its goals after reviewing safety data & exploratory efficacy results, including Forced Vital Capacity (FVC).
  • Partner Josh Wilson is encouraging investors with significant losses in Tvardi stock or options to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • The firm has offices in New York, Pennsylvania, California, & Georgia, & has recovered hundreds of millions of dollars for investors since 1995.
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.